基石藥業-B(02616.HK)在2021年ESMO年會公佈CS1002與CS1003聯合治療在晚期實體瘤患者中Ib期研究數據
格隆匯9月20日丨基石藥業-B(02616.HK)發佈公吿,基石藥業在2021年歐洲腫瘤內科學會(“ESMO”)年會上,基石藥業公佈了CS1002(抗CTLA-4單抗)與CS1003(抗PD-1單抗)聯合治療在晚期實體瘤患者中的Ib期研究(CS1002-101,NCT03523819)的初步結果(PosterID:981P)。研究數據表明,CS1002與CS1003免疫檢查點抑制劑聯合治療,在未接受過抗PD(L)1治療的微衞星高度不穩定(MSI-H)/錯配修復缺陷(dMMR)實體瘤患者與經抗PD-(L)1治療失敗的黑色素瘤患者中,均展示出了良好的安全性與令人鼓舞的抗腫瘤活性。
CS1002-101研究是一項多中心、開放性、劑量遞增和劑量擴展的Ia/Ib期研究,旨在評估CS1002單藥治療(Ia期),以及與CS1003聯合治療(Ib期)的臨牀安全性、耐受性、藥代動力學特徵和初步抗腫瘤活性。
基石藥業首席科學官謝毅釗博士表示:“細胞毒性T細胞抗原-4(“CTLA-4”)是一個重要的T細胞激活的負調因數。國內外多個靶向CTLA-4的臨牀研究正在開展,目前僅有一個針對CTLA-4靶點的單抗藥物獲批上市。此次CS1002和CS1003聯合治療在未接受過抗PD(L)1治療的MSI-H/dMMR實體瘤患者和經抗PD(L)1治療失敗的黑色素瘤患者中的臨牀療效數據令人鼓舞,並展示出良好的安全性。這些數據支援CS1002和CS1003聯合療法進一步臨牀開發。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.